Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06336291 · ClinicalTrials.gov registry record · Phase 2

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

A Phase 2 study of Glioblastoma, sponsored by Philogen S.p.A..

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
8
Study locations

NCT06336291 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by Philogen S.p.A.. The registered enrollment target is 90 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (17% lower). The trial reports 8 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06336291, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by Philogen S.p.A..

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
8
Study locations

Study Summary

The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence

Conditions Studied

Glioblastoma

Interventions

  • DRUG Lomustine
  • DRUG L19TNF

Study Locations (8)

Massachusetts

  • Massachusetts General Hospital (MGH) - Boston
  • Beth Israel Deaconess Medical Center (BIDMC) - Boston
  • Dana-Farber Cancer Institute (DFCI) - Boston

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia
  • UPMC Hillman Cancer Center - Pittsburgh

Illinois

  • Northwestern Memorial Hospital - Chicago

New York

  • Memorial Sloan Kettering Cancer Center - New York

Virginia

  • University of Virginia (UVA) - Charlottesville

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-05-22
Est. Completion 2026-06
Phase Phase 2

Sponsor

Philogen S.p.A.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06336291

The ClinicalTrials.gov registry entry for NCT06336291 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (17% lower). The listed sponsor is Philogen S.p.A., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Lomustine is the first listed.

NCT06336291 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Illinois.

Frequently Asked Questions

What is clinical trial NCT06336291 about?

NCT06336291 is a clinical study titled "A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence". The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence

What is the current status of trial NCT06336291?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-05-22. Estimated completion is 2026-06.

What conditions does trial NCT06336291 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT06336291?

The interventions under investigation include: Lomustine (DRUG), L19TNF (DRUG).

Who is sponsoring clinical trial NCT06336291?

This trial is sponsored by Philogen S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06336291 being conducted?

This trial has 8 study locations across Illinois, Massachusetts, New York, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.